| Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome (NCT05379166) | Uma Borate | 2022-06-23 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome (NCT03359460) | University of California, Davis | 2017-12-01 |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT02890329) | National Cancer Institute (NCI) | 2017-09-05 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome (NCT02553941) | Brian Jonas | 2016-05-17 |
| Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant (NCT02485535) | University of Chicago | 2015-09-04 |
| Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689) | City of Hope Medical Center | 2014-02-10 |
| Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (NCT01812252) | Fred Hutchinson Cancer Center | 2013-08-19 |
| Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01757639) | National Cancer Institute (NCI) | 2012-12-14 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219) | National Cancer Institute (NCI) | 2010-07-15 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT01132586) | National Cancer Institute (NCI) | 2010-05-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00313586) | National Cancer Institute (NCI) | 2006-08-01 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (NCT00351975) | National Cancer Institute (NCI) | 2006-06-01 |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia (NCT00357565) | Masonic Cancer Center, University of Minnesota | 2005-11-01 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001) | Fred Hutchinson Cancer Center | 2004-11-01 |